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Background : In daily clinical practice, the leukocyte count is the most common and simple inflammation parame-
ter. However, its role in predicting the clinical outcomes and prognosis of patients with acute coronary syndrome 
(ACS) is still conflicting. 
Objectives : This study aimed to assess the role of leukocytosis as the predictor of mortality in ACS patients 
undergoing percutaneous coronary intervention (PCI).
Methods : This single-centre retrospective cohort study used the STEMI registry data in Saiful Anwar General 
Hospital, Malang, Indonesia, from January to July 2019. The predictor was the leucocyte count during hospital 
admission, and the outcome was the 30-day mortality following PCI procedure. The receiver-operating character-
istic (ROC) curve was used to determine leukocyte count cut-off point, sensitivity, and specificity.
Results: The best leukocyte count cut-off value was 12300/µL, with the area under the curve (AUC) of 0.702 (95% 
CI 0.575 - 0.83), the sensitivity of 71.4%, and specificity of 61.3%. Leukocytosis increased the risk of 30-day 
mortality (74.5% vs 42.4%; OR = 3.958; 95% CI = 1.518-10.25; p = 0.014). Survival rate within 30-day after 
PCI was lowered in the leukocytosis group (the Log-Rank p = 0.002). The difference became apparent after day 
five post-PCI.
Conclusion: Leukocytosis during hospital admission is associated with increased mortality in ACS patients 







 Inflammation plays a significant role in atherosclerosis 
disease.1,2 The inflammatory cascade may serve as a promoter and 
initiator in the evolution of atherosclerosis. Inflammation also contrib-
utes to promoting fibrous cap rupture, leading to acute thrombosis and 
acute arterial occlusion. If this circumstance occurs in the coronary 
arteries, this condition may lead to the development of ACS.3,4 
Increased inflammatory markers, such as C-reactive protein, serum 
amyloid receptor A, interleukin-6, and interleukin-1, had been studied 
to be associated with poor clinical outcomes in ACS patients.1,2,5–7 
However, those inflammatory markers are not widely available because 
of their high cost and time-consuming examination process. Therefore, 
their utilization is very restricted. In daily clinical practice, leukocyte 
count is the most common and simple inflammation parameter. 
Moreover, the role of leukocyte to predict the clinical outcomes and the 
prognosis of ACS patients had been investigated by several studies.1,2 
Increased leukocyte count is associated with poor clinical outcomes, 
including a larger infarct area, decreased left ventricular function, and 
increased long-term mortality in ACS patients.8,1,9,10
In ST-elevation myocardial infarction (STEMI), the correlation between 
leukocyte count at hospital admission and mortality had been reported 
for more than 50 years. However, inconsistent findings were observed 
across the studies.1 Moreover, several scores dedicated to predicting the 
mortality of ACS patients, such as the thrombolysis in myocardial 
infarction (TIMI) risk score and global registry of acute coronary events 
(GRACE) score, do not include the leukocytosis as the predictor of 
mortality.11–13 Our current study, therefore, aimed to assess the role of 
leukocytosis as the predictor of mortality in ACS patients undergoing 
PCI. 
2. Method
2.1 Study population, exposure, and outcome
 This single-centre retrospective cohort study used the STEMI 
registry data in Saiful Anwar General Hospital, Malang, Indonesia, 
from January to July 2019. Our study was registered and approved by 
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conformed with the principles outlined in the Declaration of Helsinki. 
During the study period, we successfully collected data from 242 ACS 
patients. We included all ACS patient undergoing PCI as the revascular-
ization strategy. Exclusion criteria included: (1) unavailability of 
leukocyte count data during the hospital admission; (2) incomplete 
data; (3) infection/sepsis; (4) malignancy; and/or (5) patients who lost 
to follow up.
 The predictor covariate was the levels of leucocytes during 
hospital admission. The cut-off point of the leukocyte count was 
determined using the ROC curve. Subsequently, the patients were 
divided into two groups following the cut-off point. The outcome of this 
study was the 30-day mortality following PCI procedure. We also 
performed a subgroup analysis to determine another variable that 
contributes to predict the mortality of ACS patients treated with PCI. 
2.2. Statistical Analysis 
 The categorical data were presented in frequency (%), while 
numerical data were presented in mean and standard deviation (SD). 
The comparison between both groups was evaluated using the 
chi-square test or Fisher's exact test for categorical data. While for the 
continuous data, we used the Mann Whitney test because our data were 
not normally distributed. The cut-off point of the leukocyte count was 
determined using the ROC curve. We also conducted a bivariate 
analysis test to assess the important predictor for mortality in ACS 
patients undergoing PCI. The survival analysis using the Kaplan-Meier 
curve was performed to analyze the 30-day mortality after PCI. All data 
processing and analysis were done using Statistical Package for Social 




 Among 242 patients, we excluded a total of 162 patients 
because they did not conform to the eligibility criteria. Finally, we 
included a total of 80 patients in our analysis. Figure 1 shows the 
flowchart of patients selection in our current study. We conducted the 
analysis using the ROC curve to determine the cut-off point of 
leukocyte levels. The best leukocyte count cut-off value was 12300/µL, 
with the area AUC of 0.702 (95% CI 0.575 - 0.83), the sensitivity of 
71.4%, and specificity of 61.3%. Patients with leukocyte count ≥
12330/µL were classified as the leukocytosis group, while patients with 
leukocyte count <12330/µL were categorized as a non-leukocytosis 
group. The ROC analysis is shown in figure 2. Baseline characteristics 
of both groups were not significant, suggesting that the data were 
distributed homogenously in both groups. However, the number of 
patients with diabetes mellitus (DM) was lower in the leukocytosis 
group (12.8% vs. 42.4%; p = 0.003). The baseline characteristics of the 
study participants are summarized in Table 1.
4. Outcomes
 We conducted the bivariate analysis test to identify the 
impact of several comorbid conditions such as diabetes mellitus, 
hypertension, smoking habit, and hypertension in 30-day mortality. 
The results of the bivariate analysis test revealed that leukocytosis 
increased the risk of 30-day mortality of ACS patients who treated with 
PCI (74.5% vs 42.4%; OR = 3.958; 95% CI = 1.518-10.25; p = 0.014). 
  15
Figure 1. A flowchart of patients selection in our study
Figure 2. The receiver-operating characteristic (ROC) curve to 
determine the cut-off point of the leukocyte count. 
Figure 3. Kaplan Meier survival curves for 30-day mortality. 
Leukocyte count cut-off value = 2300/µL; AUC = 0.702; sensitivity 
= 71.4%; specificity = 61.3%. AUC = area under the curve.
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In comparison, the other comorbid factors did not show a significant 
contribution to the 30-day mortality rate in this population. Bivariate 
analysis for several comorbidities and their impact on 30-day mortality 
are summarized in Table 2. Survival analysis using the Kaplan-Meier 
5. Discussion 
 Our study revealed that leukocytosis is associated with a 
higher risk of 30-day mortality in ACS patients undergoing PCI. To the 
best of our knowledge, our study was the first study evaluating the role 
of leucocyte count during hospital admission to predict 30-day mortali-
ty in Malang, Indonesia. Our present findings were consistent with 
some previous studies. A study from Cannon et al. in ACS patients 
revealed that the levels leukocytes of more than 11000/µL were associ-
ated with a higher mortality rate during the 10-month follow-up 
period.14 In patients with myocardial infarction, the study from Barron 
et al. revealed that the levels of leukocytes within 24 hours of admission 
> 13600/µL were correlated with the higher risk of in-hospital mortali-
ty, in-hospital clinical events, and 30-day mortality.15 In Non-ST 
Elevation Myocardial Infarction (NSTEMI), a study from Dharma et al. 
revealed that the levels of leucocytes >11000/µL at hospital admission 
were the independent predictor for major adverse cardiovascular events 
(MACEs).16 However, a study from Dragu et al. which analyzed the 
subsets of leukocytes revealed that increased neutrophil count signifi-
cantly correlated with the higher mortality rate in myocardial infarction 
patients.17 Data from GRACE also demonstrated that leucocytes levels 
were the significant predictor for heart failure and in-hospital mortality 
in unstable angina, NSTEMI, and STEMI.18 Our current findings 
supported several earlier studies. However, it should be noted that not 
all patients received PCI as the revascularization strategy in the 
previous studies.14–18 A study from Palmerini et al. revealed that 
leukocytosis at the baseline was associated with a higher 12-month 
mortality rate in STEMI patients undergoing primary PCI.1
 In our study, we needed to assess the performance of 
leukocyte count during hospital admission as the predictor of 30-day 
mortality in ACS patients undergoing PCI. Our study demonstrated that 
leukocyte count ≥ 12330/µL was the predictor of 30-day mortality 
following PCI with sensitivity and specificity of 71.4% and 61.3%, 
respectively.  Our findings were not much different with the result of 
the study from Dharma et al. They demonstrated that the leucocyte
curve revealed that the survival rate within 30-day after PCI was  
lowered in the leukocytosis group with the Log-Rank p = 0.002. The 
difference became apparent after day five post-PCI. The Kaplan-Meier 
curve analysis for 30-day mortality is outlined in Figure 3.
levels >11000/µL had sensitivity and specificity of 50% and 70%, 
respectively to predict MACE in NSTEMI patients.16 Combining 
leukocyte levels and other complete blood count parameters may 
provide the better specificity and sensitivity. The study from Park et al. 
in patients with STEMI undergoing primary PCI revealed that the 
neutrophil to lymphocyte ratio (NLR) ≥5.44 had sensitivity and 
specificity of 72% and 68%, respectively, to predict mortality.19 A study 
from Çiçek et al. showed that leukocyte to mean platelet volume ratio 
≥ 1653.47 was the best predictor of poor outcome in STEMI patients 
with the sensitivity and specificity were 75.4% and 87.3%, respective-
ly.20 
 Some pathophysiological mechanisms may explain the role 
of leukocytosis in increasing mortality in ACS. There are several  mecha-
nisms in which leukocytosis impairs myocardial blood flow. First, the 
white blood cells may lead to endothelial damage through the oxidation 
and its proteolytic enzyme.21 Second, a high level of leucocyte-platelet 
aggregates may cause microvascular plugging.22 Third, the white blood 
cells may release proinflammatory mediators or cytokines. These 
mediators may affect all thrombus formation stages, such as platelet 
activation, platelet aggregation, and coagulation cascade activation.23 
Fourth, at the tissue level, monocyte activation lead to extrinsic 
pathway activation, thrombus formation, and finally, infarct area 
broadening.21,24 In myocardial infarction patients who developed 
cardiogenic shock or acute heart failure, cytokines such as tumor 
necrosis factor-α, interleukin-6, and interleukin-8 level are 
increased.25,26  This systemic inflammation condition may lead to 
massive peripheral vasodilatation because of the release of nitric oxide 
synthase and peroxynitrite. The high level of nitric oxide synthase, 
peroxynitrite release, and proinflammatory cytokines in the 
bloodstream cause ventricular dysfunction because of their cardiotoxic 
properties. The decrease in cardiac output and systemic vascular 
resistance will lead to impaired tissue perfusion, which in turn will lead 
to multiple organ dysfunction syndrome and death. 27,28  




Tabel 1. Baseline characteristics of the patients.
Note, data were presented in n(%) or mean ± SD































Table 2. The summary of our cumulative analyses regarding several comorbidities and their impact on 30-day motality 
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leukocytosis as a strong predictor of mortality in ACS patients undergo-
ing PCI in our Hospital. However, our study had several limitations. 
First, our study was a retrospective study with small sample size and a 
short follow-up period. Second, we did not perform post-PCI 
angiographic analyzes such as complete revascularization and TIMI 
flow because data were not available. Third, we did not have data on 
baseline patient characteristics regarding hemodynamic disturbances as 
reflected by the Killip class, door to wire crossing time, and the presence 
of comorbidities in more detail. Fourth, we also did not have laboratory 
and echocardiographic examination data from the patients. A study 
with a better methodology and a larger sample size is still needed to 
confirm leukocytosis performance at hospital admission as a predictor 
of mortality in ACS patients undergoing PCI. 
6. Conclusion
 Our findings reveal that leukocytosis during hospital admis-
sion is associated with increased risk of mortality in ACS patients under-
going PCI. Leucocytosis is a significant predictor of mortality within 30 
days after PCI in our population. Therefore we expected that, in the 
near future, the leukocytes levels are further investigated, and may be 
considered as the pivotal point in the scoring system to predict the risk 
of mortality among ACS patients undergoing PCI.
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